For the period of 01 July 2021 to 07 July 2021 Reviewed by: Department of Health (DOH) – Health Technology Assessment Division (HTAD) Document Link: 01 to 07 July 2022
Evidence brief for 24 to 30 June 2022
For the period of 24 to 30 June 2022. Reviewed by: Department of Health (DOH) – Health Technology Assessment Division (HTAD) Document Link: 24 to 30 June 2022
Evidence brief for 18 to 24 June 2022
For the period of 18 June 2022 to 24 June 2022 Reviewed by: Department of Health (DOH) – Health Technology Assessment Division (HTAD) Document Link: 18 to 24 June 2022
Evidence brief for 11 to 17 June 2022
For the period of 11 to 17 June 2022 Reviewed by: Department of Health (DOH) – Health Technology Assessment Division (HTAD) Document Link: 11 to 17 June 2022
Preliminary Recommendation for the Non-Inclusion of Eribulin in the Treatment of Soft Tissue Sarcoma in the PNF
Document link: Evidence Summary (Proponents may submit appeals to hta@doh.gov.ph until 28 June 2022 using the prescribed form accessible via Topic Nomination.)